Eric Faulkner, Senior Director of US Market Access and Reimbursement, has been appointed as an adjunct Assistant Professor at the Institute for Pharmacogenomics and Individualized Therapy at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill. Mr. Faulkner has gained US and international recognition as an expert in topics at the intersection of evidence-based practice, health technology assessment practices and personalized medicine, and health policy. Eric has significant experience advising on reimbursement and evidence requirements, product development and commercialization strategy, and health policy related to personalized medicine and the use of biomarkers to inform targeted therapeutic utilization.
This appointment will further encourage to collaboration among experts at RTI, UNC and other external stakeholders on research initiatives relevant to decision making and practical applications of biomarkers and personalized medicine and supports RTI International’s commitment to meaningful collaborations with founding universities: University of North Carolina, Duke University and North Carolina State University.
Mr. Faulkner’s responsibilities at RTI Health Solutions involve evaluation of US and international pricing and reimbursement issues, health technology assessment practices, product reimbursement and commercialization strategies and changing health policy. He has recently served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology and serves on the Leadership Committee of the Health Technology Assessment for Emerging Technologies Working Group of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
In addition to his role at RTI Health Solutions, Mr. Faulkner also serves as Director of the Genomic Biotech Institute (GBI) of the National Association of Managed Care Physicians (NAMCP) and is Editor-in-Chief of the GBI special section of the Journal of Managed Care Medicine, Genomics and Biotechnology.